Matthew Buten - 31 Dec 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Role: Chief Financial Officer
Signature: /s/ George Clark, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 31 Dec 2021
Net transactions value: -$871,373
Form type: 4
Filing time: 04 Jan 2022, 20:30:58 UTC
Previous filing: 14 Dec 2021
Next filing: 07 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BHVN	Common Shares	Options Exercise	$0	+12,500		$0.000000	12,500	31 Dec 2021	Direct
transaction	BHVN	Common Shares	Tax liability	$871,373	-6,323	-51%	$137.81^*	6,177	31 Dec 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BHVN	Restricted Share Unit Award	Options Exercise		-12,500	-25%		37,500	31 Dec 2021	Common Shares	12,500		Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	No shares were sold - these shares were withheld by the issuer in connection with mandatory share settlement to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F2	Each restricted share unit represents the contingent right to receive one common share of the issuer.
F3	The reporting person was granted 50,000 restricted share units on December 8, 2021. 12,500 of the restricted share units vested on December 8, 2021 and were subject to deferred settlement. The remainder vest in three equal installments on December 8, 2022, 2023 and 2024 subject to the reporting person's continued service with the issuer at each vesting date.
F4	Not applicable.